Introduction
Despite the huge success of antiretroviral therapy (ART), a cure is needed to eliminate ongoing morbidity and the unsustainable costs of maintaining those living with HIV on lifelong ART. Current ART potently suppresses HIV-1 replication; however, proviral infection still persists in a small pool of latently infected cells (the 'reservoir'). Targeting the reservoir is critical for an HIV cure and evidence suggests that a combination of interventions will be required [1] .
Immediate ART following infection can minimize the size and complexity of the latent reservoir [2, 3] and in a minority of individuals can lead to post-treatment control Correspondence: Dr J Tiraboschi, Guys and St Thomas' NHS Foundation Trust, London, UK. Tel: +44 20 7188 8610; fax: +44 20 7188 2608; e-mail: juanmanuel.tiraboschi@gstt.nhs.uk [4, 5] . Additional interventions are required; proposed strategies include the passive infusion of neutralizing antibodies [6] and kick-and-kill approaches to induce HIV reactivation to reveal hidden virus [7] . Intravenous immunoglobulin (IVIG) is used in a variety of autoimmune conditions and has been shown to temporarily reduce the viral reservoir in chronic HIV infection in the presence of ART [7, 8] .
We propose that giving IVIG at the time of acute infection will induce a change in the reservoir before the set point has been reached, thus conferring a long-term benefit in terms of the viral reservoir. We investigated whether the addition of immunoglobulin could cause reactivation of virus which would be re-suppressed by ongoing ART, thereby reducing long-term immune activation and the HIV viral reservoir.
Methods
This was a prospective, proof-of-concept, 48-week randomized study. Acutely HIV-infected adults, defined as being HIV antibody negative and p24/polymerase chain reaction (PCR) DNA positive, or being HIV antibody positive with a previous negative HIV test in the preceding 3 months, or having a positive HIV incidence assay (estimating that the virus was acquired within 3 months), were enrolled at a single site over 4 months. At enrolment, all subjects initiated four-drug ART (tenofovir, entricitabine, ritonavir-boosted darunavir and raltegravir). Blood samples were collected at baseline and at weeks 4, 12 
Reservoir and Residual viraemia
Low-copy viral load was measured with an internally controlled ultrasensitive quantitative real-time reverse transcriptaseÀpolymerase chain reaction (RT-PCR) with a limit of detection of 3 copies/mL. Purified peripheral blood CD4 T cells were analysed by quantitative PCR (qPCR) for HIV-1 DNA (total and integrated) as reported elsewhere [3] .
For preparation of the gut biopsies for HIV reservoir quantification, a commercial kit was used (Qiagen, Hilden, Germany; Cat. No. 56404), and the manufacturer's protocol was modified as follows to ensure maximum yield of DNA. Biopsy sections were removed from paraffin blocks using a scalpel and placed into 1.5-mL microcentrifuge tubes. Samples were washed repeatedly with xylene and ethanol until the precipitate had disappeared, then dried at room temperature. Biopsy sections were incubated at 37°C and DNA was extracted using a commercial kit (QIAAMP DNA FFPE Tissue Extraction Kit, ID 56404; Qiagen). The resulting DNA was eluted to yield a volume of 200 lL and analysed by qPCR using the same assays as detailed above for peripheral blood CD4 cells.
Bacterial translocation
Plasma bacterial 16S DNA was quantified by real-time PCR [9] . All samples were run in duplicate.
Immune activation and lymphocyte subsets 
Immunohistochemistry
Rectal biopsy sections were stained for CD4 (goat polyclonal; Novus Biologicals, Abingdon, UK) and CD8 (rabbit polyclonal; Abcam, Cambridge, UK) antibodies. Images were analysed in IMAGEJ (NIH, Maryland, USA) [10, 11] and the distribution of cells was determined as described elsewhere [9] .
Statistical analysis
All outcome measures were compared using the paired t-test after confirming a normal distribution of variables.
Results

Patient characteristics
All 10 individuals were male. The mean age was 31 years, the mean baseline CD4 count was 593.3 cells/lL [standard deviation (SD) 177.68 cells/lL], the mean HIV viral load was 6.0 log 10 copies/mL (SD 6.35 log 10 copies/mL) and the mean CD4:CD8 ratio was 0.61 (SD 0.3) ( Table 1 ). All individuals had wild-type virus and maintained virological suppression from week 19 to week 48. Immunoglobulin therapy was well tolerated and no viral blips (> 50 copies/ mL) occurred during IVIG therapy. Spearman's rank correlation showed a statistically nonsignificant negative relationship between baseline viral load and baseline total HIV DNA (correlation coefficient = À0.21; P = 0.56).
Primary outcome: HIV-1 reservoir
Mean total HIV DNA in PBMCs decreased in both arms from baseline to week 48 (immunoglobulin arm, À3.70 (Table 2) .
Bacterial translocation
Bacterial translocation increased from week 19 to week 48 in the immunoglobulin arm (Mean change 24.1 16S DNA copies/mL) and in the control arm (Mean change 14.8 16S DNA copies/mL), with no difference between the groups (95% CI À83.09, 101.87 16S DNA copies/mL; P = 0.8).
T-cell activation and exhaustion
There were no significant changes from week 19 to week 48 in the levels of activation of CD4 T cells and CD8 T cells (% CD4 + CD25 + , CD4 + CD38 + 38 + , CD4 + CD69 + , CD4 + HLADR + , CD8 + HLA-DR + , CD8C + D69 + , CD8 + CD38 + and CD8 + CD25 + ) or the level of immune exhaustion of markers (Pd1 and Tim3 Lag3) on CD4 T cells and CD8 T cells.
Discussion
The latent infection of resting CD4 T lymphocytes constitutes a major obstacle for the eradication of HIV. We sought to explore whether the temporary reduction in viral reservoir associated with immunoglobulin use in chronic infection [7, 8] could induce a longer term effect in those treated at the time of acute HIV infection before the viral set point has been reached. Immunoglobulin therapy was well tolerated but did not induce any viral blips during therapy. We found no impact of immunoglobulin on viral reservoir in the blood or gut or any surrogate markers of HIV (including immune activation, immune exhaustion and bacterial translocation) from baseline to week 48. The finding that such nonspecific antibodies played no role in an HIV cure is highly topical, given that several HIV-specific monoclonal antibodies-in particular, PGT121, VRC01 and VRC03-do exhibit anti-latent viral reservoir properties [12, 13] and clinical trials are underway.
In this pilot study, we did not detect a significant difference between the arms. However, the small sample size may have limited the possibility of detecting differences. Moreover, whether a different timing of the immunoglobulin administration (i.e. when the patient was first seen) would have yielded different results remains unclear.
The significant cost and invasiveness of the intervention may limit the scope for conducting the larger studies that are required to determine whether this intervention is an effective strategy.
The rapid recruitment of subjects to this study and the fact that all participants volunteered to undergo the optional gut biopsies highlight the willingness of individuals with acute HIV infection to take part in HIV cure research.
